АС

А. С. Колбин

St Petersburg University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

МА

М. А. Проскурин

St Petersburg University

YЕ

Yu. Е. Balykina

St Petersburg University

АА

А. А. Курылев

First Pavlov State Medical University of St. Petersburg

НН

Н Н Климко

North-Western State Medical University named after I.I. Mechnikov

YМ

Yu. М. Gomon

First Pavlov State Medical University of St. Petersburg

Sidorenko Sv

North-Western State Medical University named after I.I. Mechnikov

ЮЕ

Ю Е Балыкина

St Petersburg University

ТС

Т С Богомолова

North-Western State Medical University named after I.I. Mechnikov

I. A. Vilum

First Pavlov State Medical University of St. Petersburg

ТЛ

Т. Л. Галанкин

First Pavlov State Medical University of St. Petersburg

Cooperative Institutions

Sechenov University

156

First Pavlov State Medical University of St. Petersburg

147

Ministry of Health of the Russian Federation

126

Lomonosov Moscow State University

S. M. Kirov Military Medical Academy

St Petersburg University

Peoples' Friendship University of Russia

North-Western State Medical University named after I.I. Mechnikov

Pirogov Russian National Research Medical University

Chelyabinsk State University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Resolution based on the results of the III annual scientific and practical conference «Real clinical practice in a changing world. Challenges and Solutions»

Real-World Data & Evidence (2022)

А. С. Колбин

On September 29, 2022, the Association of Specialists in Health Technology Assessment, the Association of Clinical Pharmacologists, the St. Petersburg branch of the International Society for Pharmacoeconomic Research and Scientific Analysis (ISPOR) organized and held the III annual scientific and practical conference with international participation «Real clinical practice in a changing world. Challenges and Solutions». The topic of the conference brought together leading Russian and world experts in the field of RWD/ RWE.

Clinical Practice

Real world evidence

10.37489/2782-3784-myrwd-20

Cite

Citations (4)

Pharmacoeconomic analysis of insulin aspart+nicotinamide versus insulin aspart in patients with diabetes mellitus

Pharmacoeconomics theory and practice (2021)

А. С. Колбин А. А. Курылев Yu.Ye. Balykina М. А. Проскурин S. А. Mishinova

Glycemic control is a clinical goal in the treatment of diabetes mellitus. Currently available bolus insulin analogues do not follow the physiological pattern of insulin secretion after meals because they are slowly absorbed from the injection site. Insulin aspart+nicotinamide is an ultra-fast acting human insulin analog that can be administered before or after meals and the nicotinamide (vitamin B3) molecule provides optimal glycemic control. Aim. To evaluate clinical and economic efficacy of the drug insulin aspart+nicotinamide in comparison with insulin aspart in patients with diabetes mellitus. Materials and Methods. Clinical and economic analysis was performed in accordance with the standards and recommendations valid in the Russian Federation, the method of cost-effectiveness analysis for the first model population of patients with type 1 diabetes and the method of cost-minimization analysis for the second model population of patients with type 2 diabetes, modeling horizon was 26 weeks. Since the study is conducted from the per- spective of the health care system only direct medical costs were considered, that is, the cost of insulin therapy and the cost of complications treatment (hypoglycemia). During the budget impact analysis, the source of data on the target population was the registry of patients with diabetes mellitus of the Russian Federation. Probabilistic sensitivity analysis was performed to assess the impact of changes in the input parameters of the models. Results. Insulin aspart+nicotinamide has a clinical advantage in the effective- ness of HbA1c reduction in type 1 diabetes population. In patients with type 2 diabetes, the effectiveness of insulin aspart+nicotinamide and insulin aspart is comparable by a similar criterion. Direct medical costs of insulin aspart+nicotinamide are 10.64% lower in comparison with insulin aspart use in type 1 and type 2 diabetes patients’ population. The CER value in type 1 diabetes patient population for insulin aspart is 70% higher compared to insulin aspart+nicotinamide (7,410,353.83 and 4,348,513.94 RUR respectively). Budget impact analysis results are the following: that complete replacement of insulin aspart with insulin aspart+nicotinamide over 3 years is accompanied by a 5.3% reduction of regional drug benefit budget costs. Conclusion. The clinical and economic analysis confirms the economic feasibility of insulin aspart + nicotinamide use

Insulin aspart

10.30809/phe.4.2021.1

Cite

Citations (0)

Clinical Pharmacology for Pediatricians

А. С. Колбин

Clinical Pharmacology

10.33029/9704-5920-1-cph-2021-1-288

Cite

Citations (0)

Управление клиническими исследованиями

А. С. Колбин С.К. Зырянов Д.Ю. Белоусов

Source

Cite

Citations (0)

PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS

Value in Health (2019)

Y. Yurkova А. А. Курылев А. С. Колбин

10.1016/j.jval.2019.09.455

Cite

Citations (0)

СОЦИАЛЬНО-ЭКОНОМИЧЕСКОЕ БРЕМЯ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ В РОССИИ: ДИНАМИКА ЗА 7 ЛЕТ (2010-2017 ГОДЫ)

Journal of Arrhythmology (2018)

А. С. Колбин Anna A Mosikian Б. А. Татарский

To assess the socioeconomic burden of AF in Russia taking epidemiologic trends into the account, coming of new AF treatment guidelines into effect, and implementation of national standards of management, the analysis of available data pharmacoeconomic billing were made.

Source

Cite

Citations (0)

Medical technologies assessment in COVID-19

HIV Infection and Immunosuppressive Disorders (2023)

А. С. Колбин Yu. М. Gomon

According to official information about the coronavirus, as of May 2023, about 400 thousand people died from COVID-19 in Russia, 6.9 million people in the world. Social, as well as medical and economic aspects are associated with the COVID-19 pandemic. The main global financial resources were allocated to the provision of vaccines ($13.8 billion, 40.4%); reorganization of health systems ($4.1 billion); COVID-19 drug therapy ($3.4 billion). The costs of research, development and study of vaccines and medicines accounted for only 0.6% of total costs ($166 million). The article presents a clinical and pharmacological analysis of various medicines recommended for the treatment of infection. In these conditions, the reliability and effectiveness of national health technology assessment systems has become particularly relevant.

Pandemic

2019-20 coronavirus outbreak

Health Technology

10.22328/2077-9828-2023-15-3-105-115

Cite

Citations (1)

[Clinical and economic expedience of ertapenem therapy of complicated urinary tract infection].

PubMed (2011)

А. С. Колбин Sidorenko Sv Ksenia Zagorodnikova В. Б. Мусатов Iakovlev Aa

Clinical and economic investigation of various antibiotics use in the treatment of complicated urinary tract infection (CUTI) was performed under the Russian economic environment. The drugs of comparison were ertapenem, ceftriaxone and levofloxacin. Direct costs and their structure were shown, and the cost efficiency was calculated. Alternative analysis and one-side susceptibility analysis were performed. In complicated urinary tract infections when the major pathogens were Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis it was clinically and economically reasonable to start the treatment with ceftriaxone or ertapenem, while levofloxacin could be an alternative strategy. When the effects of the acquired resistance on the treatment effectiveness were evaluated (SIS model) it was shown that the pathogens susceptibility to ertapenem was preserved for a significantly longer time than that to ceftriaxone or levofloxacin (60 months). Such a parameter may serve as an additional evidence of the reasonable use of ertapenem as the starting treatment of CUTI.

Ertapenem

Source

Cite

Citations (1)

НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ ИНТЕРФЕРОНОВ СИСТЕМНОГО ДЕЙСТВИЯ

Safety and Risk of Pharmacotherapy (2015)

Александр Андреевич Топоров А. С. Колбин

Objective: To explore the profile of adverse events associated with interferon therapy. Design: Systematic review. Data sources: Electronic and paper records in subject area from 2000 to 2014. Methods: We searched for the studies on safety and tolerability containing adverse events of interferons with systemic effect. Results: The most frequent adverse events were: flu-like syndrome (55%), depression (30%), neutropenia (20%), anemia (13%). Conclusion: Adverse events are a very serious problem of interferon treatment. System of pharmacovigilance provides forecasting and early identification of these adverse events, as they are predictable.

Tolerability

Leukopenia

Source

Cite

Citations (0)

The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2022)

А. С. Колбин A. A. Kurilev Y. E. Balikina М. А. Проскурин

Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim . Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods . Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA 1c ) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results : Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA 1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion . Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.

Glycated hemoglobin

Insulin detemir

Insulin aspart

10.37489/2588-0519-2022-1-4-16

Cite

Citations (0)